This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Cancer in Slovenia 2013. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2016.Cancer in Slovenia 2013. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer RegistryCancer Registry of Republic of Slovenia2016Search in Google Scholar
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. 10.1515/raon-2017-0008ZadnikVPrimic ZakeljMLokarKJarmKIvanusUZagarT.Cancer burden in slovenia with the time trends analysisRadiol Oncol201751475510.1515/raon-2017-0008Open DOISearch in Google Scholar
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403. 10.1016/j.ejca.2012.12.027FerlayJSteliarova-FoucherELortet-TieulentJRossoSCoeberghJWWComberHCancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Eur J Cancer201349137440310.1016/j.ejca.2012.12.027Open DOISearch in Google Scholar
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v194-7. 10.1093/annonc/mdv297DummerRHauschildALindenblattNPentheroudakisGKeilholzU.Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol2010215v194710.1093/annonc/mdv297Open DOISearch in Google Scholar
Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014; 5: 1701-52. 10.18632/oncotarget.1892ShtivelmanEDaviesMQHwuPYangJLotemMOrenMPathways and therapeutic targets in melanomaOncotarget2014517015210.18632/oncotarget.1892Open DOISearch in Google Scholar
COSMIC, Catalogue of Somatic Mutations in Cancer. [citated 2017 Oct 10]. Available at http://cancer.sanger.ac.uk/cosmicCOSMIC, Catalogue of Somatic Mutations in Cancer. [citated 2017 Oct 10]Available athttp://cancer.sanger.ac.uk/cosmicSearch in Google Scholar
Mandalà M, Voit C.Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol 2013; 87: 239-55. 10.1016/j.critrevonc.2013.01.003MandalàMVoitC.Targeting BRAF in melanoma: biological and clinical challengesCrit Rev Oncol Hematol2013872395510.1016/j.critrevonc.2013.01.003Open DOISearch in Google Scholar
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15: 323-32. 10.1016/S1470-2045(14)70012-9McArthurGAChapmanPBRobertCLarkinJHaanenJBDummerRSafety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyLancet Oncol2014153233210.1016/S1470-2045(14)70012-9Open DOISearch in Google Scholar
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30: 2522-9. 10.1200/JCO.2011.41.2452ColombinoMCaponeMLissiaACossuARubinoCDe GiorgiVBRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanomaJ Clin Oncol2012302522910.1200/JCO.2011.41.245222614978Open DOISearch in Google Scholar
Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-23. 10.1002/cncr.26724JakobJABassettRL JrNgCSCurryJLJosephRWAlvaradoGCNRAS mutation status is an independent prognostic factor in metastatic melanomaCancer201211840142310.1002/cncr.26724331096122180178Open DOISearch in Google Scholar
Curtin JA, Busam K, Pinkel D, Bastian BC. Curtin JA, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6. 10.1200/JCO.2006.06.2984CurtinJABusamKPinkelDBastianBC.CurtinJASomatic activation of KIT in distinct subtypes of melanomaJ Clin Oncol2006244340610.1200/JCO.2006.06.298416908931Open DOISearch in Google Scholar
Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur Acad Dermatol Venereol 2015; 29:1530-8. 10.1111/jdv.12910PrachtMMoghaALespagnolAFautrelAMouchetNLe GallFPrognostic and predictive values of oncogenic BRAF NRAS, c-KIT and MITF in cutaneous and mucous melanomaJ Eur Acad Dermatol Venereol2015291530810.1111/jdv.1291025623140Open DOISearch in Google Scholar
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47. 10.1056/NEJMoa050092CurtinJAFridlyandJKageshitaTPatelHNBusamKJKutznerHDistinct sets of genetic alterations in melanomaN Engl J Med200535321354710.1056/NEJMoa05009216291983Open DOISearch in Google Scholar
Kim SY, Kim HJ, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Meanalysis of BRAF mutations and clinical-pathologiy characteistics in primary melanoma. J Am Acad Dermatol 2015; 72: 1036-46.e2. 10.1016/j.jaad.2015.02.1113KimSYKimHJHahnHJLeeYWChoeYBAhnKJ.Meanalysis of BRAF mutations and clinical-pathologiy characteistics in primary melanomaJ Am Acad Dermatol201572103646e210.1016/j.jaad.2015.02.111325819940Open DOISearch in Google Scholar
Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res 2015; 25: 9-14. 10.1097/CMR.0000000000000091YamazakiNTanakaRTsutsumidaANamikawaKEguchiHOmataWBRAF V600 mutations and pathological features in Japanese melanoma patientsMelanoma Res20152591410.1097/CMR.0000000000000091427656825051202Open DOISearch in Google Scholar
Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinical-pathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-9. 10.1158/1078-0432.CCR-12-0052MenziesAMHayduLEVisintinLCarlinoMSHowleJRThompsonJFDistinguishing clinical-pathologic features of patients with V600E and V600K BRAF-mutant metastatic melanomaClin Cancer Res2012183242910.1158/1078-0432.CCR-12-005222535154Open DOISearch in Google Scholar
Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-51. 10.1111/j.1755-148X.2011.00837.xBauerJBüttnerPMuraliROkamotoIKolaitisNALandiMTBRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor sitePigment Cell Melanoma Res2011243455110.1111/j.1755-148X.2011.00837.x310797421324100Open DOISearch in Google Scholar
Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 2014; 111: 292-9. 10.1038/bjc.2014.287CarlinoMSHayduLEKakavandHMenziesAMHamiltonALYuBCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanomaBr J Cancer2014111292910.1038/bjc.2014.287410294224918823Open DOISearch in Google Scholar
Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011; 24: 666-72. 10.1111/j.1755-148X.2011.00873.xDevittBLiuWSalemiRWolfeRKellyJTzenCYClinical outcome and pathological features associated with NRAS mutation in cutaneous melanomaPigment Cell Melanoma Res2011246667210.1111/j.1755-148X.2011.00873.x21615881Open DOISearch in Google Scholar
Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-84. 10.1111/j.1365-2133.2010.10185.xLeeJHChoiJWKimYS.Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysisBr J Dermatol20111647768410.1111/j.1365-2133.2010.10185.x21166657Open DOISearch in Google Scholar
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63. 10.1016/j.cell.2012.06.024HodisEWatsonIRKryukovGVAroldSTImielinskiMTheurillatJPA landscape of driver mutations in melanomaCell20121502516310.1016/j.cell.2012.06.024360011722817889Open DOISearch in Google Scholar
Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer 2017; 81: 106-15. 10.1016/j.ejca.2017.05.015ValachisAUllenhagGJ.Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysisEur J Cancer2017811061510.1016/j.ejca.2017.05.01528623774Open DOISearch in Google Scholar
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinical-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46. 10.1200/JCO.2010.32.4327LongGVMenziesAMNagrialAMHayduLEHamiltonALMannGJPrognostic and clinical-pathologic associations of oncogenic BRAF in metastatic melanomaJ Clin Oncol20112912394610.1200/JCO.2010.32.432721343559Open DOISearch in Google Scholar
Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8. 10.1097/01.cmr.0000232300.22032.86Edlundh-RoseEEgyháziSOmholtKMånsson-BrahmeEPlatzAHanssonJNRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencingMelanoma Res200616471810.1097/01.cmr.0000232300.22032.8617119447Open DOISearch in Google Scholar
Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015; 3: 288-95. 10.1158/2326-6066.CIR-14-0207.JohnsonDBLovlyCMFlavinMPanageasKSAyersGDZhaoZImpact of NRAS mutations for patients with advanced melanoma treated with immune therapiesCancer Immunol Res201532889510.1158/2326-6066.CIR-14-0207435179725736262Open DOISearch in Google Scholar
Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-34. 10.1001/jama.2011.746CarvajalRDAntonescuCRWolchokJDChapmanPBRomanRATeitcherJKIT as a therapeutic target in metastatic melanomaJAMA201130523273410.1001/jama.2011.746398603921642685Open DOISearch in Google Scholar
